engleski

VWF-FVIII concentrates in the treatment of inherited von Willebrand disease: A single-centre retrospective study

Only a minority of VWD patients needed treatment with VWF concentrate, namely 18% of all VWD patients followed at our center during the 15-year study period. Besides Type 3 VWD, VWF concentrates were commonly used in patients with severe disease, regardless of VWD type. In case of mild and moderate disease, the treatment modality mostly depended on the indication for hemostatic therapy. Our study has confirmed that the absolute indications for using VWF concentrates in VWD patients are prophylaxis, major surgeries, and nonresponsiveness/ contraindications to DDAVP.

von Willebrand disease ; VWF concentrate ; DDAVP ; treatment ; prophylaxis

nije evidentirano